Company Filing History:
1 out of 1,745 
1 out of 38 
1 out of 6 Years Active: 2022
Introduction
Mathieu Kerbiriou is an accomplished inventor based in Brest, France, renowned for his significant contributions to the field of medical research. With a focus on cystic fibrosis, Kerbiriou's work has led to innovative solutions aimed at addressing the challenges posed by reduced CFTR function. His research has the potential to impact numerous lives affected by this condition.
Latest Patents
Kerbiriou holds a patent titled "Methods and pharmaceutical compositions for the treatment of diseases associated with reduced CFTR function." This invention highlights the role of Activating Transcription Factor 6 (ATF6) in the repression of cystic fibrosis transmembrane conductance regulator (CFTR) and explores the therapeutic possibilities of UPR regulation. Notably, the use of a site-1 protease (S1P) inhibitor, such as PF-429242, has been shown to partially restore the membrane localization and function of the F508del-CFTR protein. This patent presents a promising method for treating diseases related to reduced CFTR function by administering a therapeutically effective amount of an S1P inhibitor to affected subjects.
Career Highlights
Throughout his career, Mathieu Kerbiriou has collaborated with esteemed institutions, enhancing his research and innovation capabilities. He has had a significant tenure at the Institut National de la Santé et de la Recherche Médicale (INSERM) and at the Université de Bretagne Occidentale, where he has contributed to groundbreaking research in medical science.
Collaborations
Kerbiriou's innovative journey has been enriched by collaboration with notable colleagues, including Pascal Trouvé and Claude Ferec. Together, they have tackled complex research problems and advanced the understanding of cystic fibrosis and related research avenues.
Conclusion
Mathieu Kerbiriou's commitment to advancing medical science is exemplified through his patent and collaborative efforts. His work has the potential to pave the way for effective treatments and improve the quality of life for individuals suffering from diseases associated with reduced CFTR function. As he continues to forge new paths in innovation, the medical community eagerly anticipates his future contributions.